Fatcube AI
AI medical imaging software that helps medical professionals triage skin moles for melanoma risk
Highlights
- New on EvolcAdded 2026-11-05
About Fatcube AI
FatCube AI develops AI-powered medical devices, including Nevus AI, a software-as-a-medical-device platform that assesses mole images and classifies malignancy risk. Its decision-support models are designed to assist clinicians, not replace their judgement.
The company’s research team builds and tests AI models for medical-image classification. Nevus AI combines six AI agents trained on four datasets; suspected melanoma cases can be referred to a dermatologist for further investigation.
FatCube AI Limited is a UK company founded in 2018 and headquartered in Wembley.
Product: Nevus AI, a medical-imaging software device that classifies malignancy risk from mole images, plus AI models for clinical imaging.
Jobs at Fatcube AI
More health & medtech companies
Fava Health
Genomics integration software and implementation services for health systems and clinical care providersYoung companyNew on EvolcFearsome
Medical device design and development services for companies in the medical and healthcare industriesNew on EvolcFeedback Medical
Digital care pathway and clinical communication software for healthcare providers, including NHS organisationsNew on EvolcFemeda
Develops female-health medical devices for women with urinary incontinence and pelvic floor weaknessNew on EvolcFertifa
Reproductive healthcare benefits and clinical support for employers and their employees in the UK and EuropeNew on EvolcRemote-friendlySalary transparentFertility Mapper
Fertility clinic comparison and matching services for people exploring treatment, egg freezing or NHS funding in the UKNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- SquarespaceHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.